Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03637517 · ClinicalTrials.gov registry record · Phase 1
Malaria: Relative Bioavailability and Food Effect of DSM265
A Phase 1 study, sponsored by Medicines for Malaria Venture.
- Completed
- Registry status
- Phase 1
- Development phase
- 42
- Enrollment target
NCT03637517: Completed Phase 1 study, sponsored by Medicines for Malaria Venture.
NCT03637517 is a Phase 1 study that has completed, run by Medicines for Malaria Venture. The registered enrollment target is 42 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03637517, a Phase 1 study, has completed, sponsored by Medicines for Malaria Venture.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 42 participants
- Enrollment target
Study Summary
Phase 1 study designed to evaluate the relative bioavailability of a single dose of a test formulation, DSM265-TPGS 34% SDD powder in comparison with a reference DSM265 25% SDD powder formulation used in early clinical trials.
Interventions
- DRUG DSM265-TPGS 34% SDD, 400 mg fasted
- DRUG DSM265-TPGS 34% SDD, 400 mg fed
- DRUG DSM265 25% SDD, 400 mg fasted
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2018-10-03 |
| Est. Completion | 2018-11-19 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03637517
The ClinicalTrials.gov registry entry for NCT03637517 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 42 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Medicines for Malaria Venture, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which DSM265-TPGS 34% SDD, 400 mg fasted is the first listed.
NCT03637517 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03637517 about?
NCT03637517 is a clinical study titled "Malaria: Relative Bioavailability and Food Effect of DSM265". Phase 1 study designed to evaluate the relative bioavailability of a single dose of a test formulation, DSM265-TPGS 34% SDD powder in comparison with a reference DSM265 25% SDD powder formulation used in early clinical trials.
What is the current status of trial NCT03637517?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 42 participants. The study started on 2018-10-03. Estimated completion is 2018-11-19.
What interventions are being tested in trial NCT03637517?
The interventions under investigation include: DSM265-TPGS 34% SDD, 400 mg fasted (DRUG), DSM265-TPGS 34% SDD, 400 mg fed (DRUG), DSM265 25% SDD, 400 mg fasted (DRUG).
Who is sponsoring clinical trial NCT03637517?
This trial is sponsored by Medicines for Malaria Venture, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.